NewzThe neural implant company Science Corporation successfully placed its PRIMA chip in the first clinical trial patient suffering from Stargardt disease, a form of inherited macular degeneration. The breakthrough was announced on Tuesday by the company's chief executive officer, Max Hodak, while speaking at the TechCrunch Disrupt event.
The technology is designed to partially restore vision in patients affected by this degenerative eye condition. This milestone marks a significant step forward in the clinical development of neural implant technologies aimed at treating retinal diseases.
In-depth summary · AI, neutral